Patents by Inventor Gregory S. Shen
Gregory S. Shen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8394414Abstract: Drug delivery to the pulmonary system has been achieved by encapsulation of the drug to be delivered in microparticles having a size range between 0.5 and ten microns, preferably in the range of two to five microns, formed of a material releasing drug at a pH of greater than 6.4. In a preferred embodiment, the drug delivery system is based on the formation of diketopiperazine microparticles which are stable at a pH of 6.4 or less and unstable at pH of greater than 6.4, or which are stable at both acidic and basic pH, but which are unstable at pH between about 6.4 and 8. Other types of materials can also be used, including biodegradable natural and synthetic polymers, such as proteins, polymers of mixed amino acids (proteinoids), alginate, and poly(hydroxy acids). In another embodiment, the microparticles have been modified to effect targeting to specific cell types and to effect release only after reaching the targeted cells.Type: GrantFiled: November 12, 2003Date of Patent: March 12, 2013Assignee: MannKind CorporationInventors: Solomon S. Steiner, Robert Feldstein, Huiling Lian, Christopher A. Rhodes, Gregory S. Shen
-
Publication number: 20040192886Abstract: The present invention is to &mgr;-conopeptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated sodium channels. Thus, the &mgr;-conopeptides or derivatives are useful as neuromuscular blocking agents, local anesthetic agents, analgesic agents and neuroprotective agents. The &mgr;-conopeptides are also useful for treating neuromuscular disorders. The invention is further directed to nucleic acid sequences encoding the &mgr;-conopeptides and encoding propeptides, as well as the propeptides.Type: ApplicationFiled: April 21, 2004Publication date: September 30, 2004Applicants: The University of Utah Research Foundation, Cognetix, Inc.Inventors: Baldomero M. Olivera, J. Michael McIntosh, James E. Garrett, Maren Watkins, Lourdes J. Cruz, Ki-Joon Shon, Richard B. Jacobsen, Robert M. Jones, G. Edward Cartier, Gregory S. Shen, John D. Wagstaff
-
Patent number: 6767895Abstract: The invention relates to relatively short peptides (termed I-conotoxins herein), about 30-50 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include four disulfide bonds.Type: GrantFiled: June 29, 2001Date of Patent: July 27, 2004Assignees: Cognetix, Inc., University of Utah Research FoundationInventors: Craig S. Walker, Reshma Shetty, Elsie C. Jimenez, J. Michael McIntosh, Baldomero M. Olivera, Maren Watkins, Robert M. Jones, Gregory S. Shen
-
Publication number: 20040096403Abstract: Drug delivery to the pulmonary system has been achieved by encapsulation of the drug to be delivered in microparticles having a size range between 0.5 and ten microns, preferably in the range of two to five microns, formed of a material releasing drug at a pH of greater than 6.4. In a preferred embodiment, the drug delivery system is based on the formation of diketopiperazine microparticles which are stable at a pH of 6.4 or less and unstable at pH of greater than 6.4, or which are stable at both acidic and basic pH, but which are unstable at pH between about 6.4 and 8. Other types of materials can also be used, including biodegradable natural and synthetic polymers, such as proteins, polymers of mixed amino acids (proteinoids), alginate, and poly(hydroxy acids). In another embodiment, the microparticles have been modified to effect targeting to specific cell types and to effect release only after reaching the targeted cells.Type: ApplicationFiled: November 12, 2003Publication date: May 20, 2004Applicant: MannKind CorporationInventors: Solomon S. Steiner, Robert Feldstein, Huiling Lian, Christopher A. Rhodes, Gregory S. Shen
-
Publication number: 20030050234Abstract: The present invention is to &mgr;-conopeptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated sodium channels. Thus, the &mgr;-conopeptides or derivatives are useful as neuromuscular blocking agents, local anesthetic agents, analgesic agents and neuroprotective agents. The &mgr;-conopeptides are also useful for treating neuromuscular disorders. The invention is further directed to nucleic acid sequences encoding the &mgr;-conopeptides and encoding propeptides, as well as the propeptides.Type: ApplicationFiled: July 23, 2001Publication date: March 13, 2003Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Baldomero M. Olivera, J. Michael McIntosh, James E. Garrett, Maren Watkins, Lourdes J. Cruz, Ki-Joon Shon, Richard B. Jacobsen, Robert M. Jones, G. Edward Cartier, Gregory S. Shen, John D. Wagstaff
-
Patent number: 6515103Abstract: The present invention is directed to conantokin peptides, conantokin peptide derivatives and conantokin peptide chimeras, referred to collectively as conantokins, having 10-30 amino acids, including preferably two or more &ggr;-carboxyglutamic acid residues. The conantokins are useful for the treatment of neurologic and psychiatric disorders, such as anticonvulsant agents, neuroprotective agents or analgesic agents.Type: GrantFiled: May 11, 2000Date of Patent: February 4, 2003Assignees: University of Utah Research Foundation, Cognetix, Inc., Salk InstituteInventors: Fe C. Abogadie, Lourdes J. Cruz, Baldomero M. Olivera, Craig Walker, Clark Colledge, David R. Hillyard, Elsie Jimenez, Richard T. Layer, Li-Ming Zhou, Gregory S. Shen, R. Tyler McCabe, Jean E. Rivier
-
Publication number: 20030017211Abstract: Drug delivery to the pulmonary system has been achieved by encapsulation of the drug to be delivered in microparticles having a size range between 0.5 and ten microns, preferably in the range of two to five microns, formed of a material releasing drug at a pH of greater than 6.4. In a preferred embodiment, the drug delivery system is based on the formation of diketopiperazine microparticles which are stable at a pH of 6.4 or less and unstable at pH of greater than 6.4, or which are stable at both acidic and basic pH, but which are unstable at pH between about 6.4 and 8. Other types of materials can also be used, including biodegradable natural and synthetic polymers, such as proteins, polymers of mixed amino acids (proteinoids), alginate, and poly(hydroxy acids). In another embodiment, the microparticles have been modified to effect targeting to specific cell types and to effect release only after reaching the targeted cells.Type: ApplicationFiled: August 2, 2002Publication date: January 23, 2003Applicant: Pharmaceutical Discovery CorporationInventors: Solomon S. Steiner, Robert Feldstein, Huiling Lian, Christopher A. Rhodes, Gregory S. Shen
-
Patent number: 6428771Abstract: Drug delivery to the pulmonary system has been achieved by encapsulation of the drug to be delivered in microparticles having a size range between 0.5 and ten microns, preferably in the range of two to five microns, formed of a material releasing drug at a pH of greater than 6.4. In a preferred embodiment, the drug delivery system is based on the formation of diketopiperazine microparticles which are stable at a pH of 6.4 or less and unstable at pH of greater than 6.4, or which are stable at both acidic and basic pH, but which are unstable at pH between about 6.4 and 8. Other types of materials can also be used, including biodegradable natural and synthetic polymers, such as proteins, polymers of mixed amino acids (proteinoids), alginate, and poly(hydroxy acids). In another embodiment, the microparticles have been modified to effect targeting to specific cell types and to effect release only after reaching the targeted cells.Type: GrantFiled: May 15, 1995Date of Patent: August 6, 2002Assignee: Pharmaceutical Discovery CorporationInventors: Solomon S. Steiner, Robert Feldstein, Huiling Lian, Christopher A. Rhodes, Gregory S. Shen
-
Publication number: 20020102607Abstract: The invention relates to relatively short peptides (termed I-conotoxins herein), about 30-50 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include four disulfide bonds.Type: ApplicationFiled: June 29, 2001Publication date: August 1, 2002Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATIONInventors: Craig S. Walker, Reshma Shetty, Elsie C. Jimenez, J. Michael McIntosh, Baldomero M. Olivera, Maren Watkins, Robert M. Jones, Gregory S. Shen
-
Patent number: 6071497Abstract: Drug delivery to the pulmonary system has been achieved by encapsulation of the drug to be delivered in microparticles having a size range between 0.5 and ten microns, preferably in the range of two to five microns, formed of a material releasing drug at a pH of greater than 6.4. In a preferred embodiment, the drug delivery system is based on the formation of diketopiperazine microparticles which are stable at a pH of 6.4 or less and unstable at pH of greater than 6.4, or which are stable at both acidic and basic pH, but which are unstable at pH between about 6.4 and 8. Other types of materials can also be used, including biodegradable natural and synthetic polymers, such as proteins, polymers of mixed amino acids (proteinoids), alginate, and poly(hydroxy acids). In another embodiment, the microparticles have been modified to effect targeting to specific cell types and to effect release only after reaching the targeted cells.Type: GrantFiled: April 24, 1997Date of Patent: June 6, 2000Assignee: Pharmaceutical Discovery CorporationInventors: Solomon S. Steiner, Robert Feldstein, Huiling Lian, Christopher A. Rhodes, Gregory S. Shen
-
Patent number: 5503852Abstract: Drug delivery systems have been developed based on the formation of diketopiperazine (or analogs) microparticles. In the preferred embodiment the microparticle is stable at low pH and disintegrates at physiological pH, and is particularly useful for oral drug delivery. In other embodiments, the microparticles are stable at high pH and disintegrate at neutral or basic pH, or are stable at neutral pH and disintegrate at high or low pH. In the most preferred embodiment the microparticles are formed in the presence of the drug to be delivered, for example, insulin, felbamate, calcitonin or heparin. The diketopiperazine synthetic intermediates are preferably formed by cyclodimerization to form diketopiperazine derivatives at elevated temperatures under dehydrating conditions, functionalized on the side chains, and then precipitated with drug to be incorporated into microparticles.Type: GrantFiled: September 1, 1994Date of Patent: April 2, 1996Assignee: Pharmaceutical Discovery CorporationInventors: Solomon S. Steiner, Christopher A. Rhodes, Gregory S. Shen, R. Tyler McCabe